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Translational Relevance 49 
 50 
This is the first Next Generation Sequencing (NGS) study of such a large, prospective cohort 51 
using a targeted gene panel, the Lymphopanel, focusing on genes identified as important for 52 
lymphomagenesis or whose potential has been pinpointed in Whole Exome Sequencing 53 
studies. Particular attention has been paid to the inclusion of actionable targets in the 54 
Lymphopanel, highlighting potential candidate patients for novel personalized therapies. This 55 
study further details subtype-enriched gene and pathway mutations in order to optimize 56 
DLBCL treatment, and highlights several novel, frequent, and actionable mutations, notably 57 
in PMBL. In addition, Lymphopanel NGS has enabled the detection of novel clinical and 58 
prognostic correlations, potentially impacting treatment decisions. As benchtop sequencers 59 
become increasingly available in academic research and routine clinical settings, our study 60 
demonstrates the feasibility and impact of NGS with a consensus gene panel in DLBCL 61 
patient management, contributing essential information to today’s precision therapy era 62 
treatment decisions. 63 
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 83 
Abstract  84 
 85 
Purpose: Next Generation Sequencing (NGS) has detailed the genomic characterization of 86 
Diffuse Large B Cell Lymphoma (DLBCL) by identifying recurrent somatic mutations. We 87 
set out to design a clinically feasible NGS panel focusing on genes whose mutations hold 88 
potential therapeutic impact. Furthermore, for the first time, we evaluated the prognostic value 89 
of these mutations in prospective clinical trials. 90 
Experimental Design: A Lymphopanel was designed to identify mutations in 34 genes, 91 
selected according to literature data and a whole exome sequencing study of 92 
relapsed/refractory DLBCL patients. The tumor DNA of 215 patients with CD20+ de novo 93 
DLBCL in the prospective, multicenter and randomized LNH-03B LYSA clinical trials was 94 
sequenced to deep, uniform coverage with the Lymphopanel. Cell of origin molecular 95 
classification was obtained through gene expression profiling with HGU133+2.0 Affymetrix 96 
GeneChip arrays. 97 
Results: The Lymphopanel was informative for 96% of patients. A clear depiction of DLBCL 98 
subtype molecular heterogeneity was uncovered with the Lymphopanel, confirming that 99 
Activated B Cell-like (ABC), Germinal Center B-cell like (GCB) and Primary Mediastinal B-100 
cell Lymphoma (PMBL) are frequently affected by mutations in NFkB, epigenetic, and JAK-101 
STAT pathways respectively. Novel truncating immunity pathway, ITPKB, MFHAS1 and 102 
XPO1 mutations were identified as highly enriched in PMBL. Notably, TNFAIP3 and GNA13 103 
mutations in ABC patients treated with R-CHOP were associated with significantly less 104 
favorable prognoses. 105 
Conclusions: This study demonstrates the contribution of NGS with a consensus gene panel 106 
to personalized therapy in DLBCL, highlighting subtypes’ molecular heterogeneity and 107 
identifying somatic mutations with therapeutic and prognostic impact. 108 
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 117 
 118 
Introduction 119 
 120 
Diffuse large B-cell lymphoma (DLBCL) is the most common form of adult lymphoma 121 
worldwide, accounting for 30-40% of newly diagnosed Non-Hodgkin Lymphoma (NHL)(1). 122 
Gene expression profiling (GEP) has made strides in deciphering the molecular heterogeneity 123 
of DLBCL, enabling the entity’s subdivision into three main molecular subtypes: Germinal 124 
Center B-cell like (GCB), Activated B-Cell like (ABC), and Primary Mediastinal B-cell 125 
Lymphoma (PMBL)(2,3). Among other genetic aberrations, the GCB subtype is characterized 126 
by t(14;18)(q32;q21) translocations(4) and loss of PTEN(5), while the ABC subtype is 127 
characterized by t(3;14)(q27;q32) translocations, deletion of the INK4A-ARF locus(6) and 128 
BCL2 amplification(7). PMBL displays strong molecular similarities to classical Hodgkin 129 
Lymphoma (cHL), exhibiting frequent amplifications of JAK2 and deletions of SOCS1(8,9). 130 
Arising from B cells at distinct stages of differentiation and maturation, these subtypes are 131 
also diverse in clinical presentation, response to immunochemotherapy and outcome, with the 132 
ABC subtype having the most unfavorable prognosis(2,7). As targeted therapies become 133 
increasingly widespread, it is essential to thoroughly characterize each molecular subtype, in 134 
order to ensure optimal care for each patient. Unfortunately, the cell of origin (COO) 135 
classification of DLBCL still has relatively little influence on clinical practice, as GEP is 136 
poorly transposable to routine diagnosis and surrogate immunohistochemical algorithms 137 
remain unreliable(10), although recent techniques offer better bench to bedside 138 
translation(11,12). 139 
Next generation sequencing (NGS) technologies, enabling high-throughput DNA sequencing, 140 
have emerged over the past decade and have provided new insights into the genomic 141 
characterization of DLBCL by identifying recurrent single nucleotide variants (SNVs), which 142 
can be enriched in a particular subtype(13–22). Although DLBCL is defined by widespread 143 
genetic heterogeneity, several of the pinpointed recurrent SNVs warrant special interest as 144 
they occur in actionable targets and/or correlate with antitumoral response. Equally of note, 145 
despite their probable physiopathological relevance, neither the prognostic value of these 146 
mutations nor their potential to predict resistance to conventional B-cell lymphoma 147 
immunochemotherapy treatment has been properly evaluated in prospective clinical trials. 148 
Furthermore, mutation feature analyses have identified activation-induced cytidine deaminase 149 
(AID)-driven somatic hypermutation (SHM) as a mechanism mediating the development of 150 
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some of these recurrent SNVs, rendering the task of distinguishing driver from passenger 151 
mutations even more challenging(23). 152 
To more feasibly identify molecular subtypes and reach the goal of precision therapy in 153 
DLBCL, a limited and clinically relevant panel of target genes must be designed, with efforts 154 
made to thoroughly describe the SNVs they harbor. Furthermore, compact sequencers readily 155 
available in academic laboratories must be used in order to generalize this practice and apply 156 
it to routine clinical disease management. With this idea in mind, we developed a 157 
Lymphopanel NGS assay, designed to identify mutations in 34 genes important for 158 
lymphomagenesis based on a literature review of WES studies in DLBCL(13,14,20,24) as 159 
well as a WES study of relapsed/refractory DLBCL cases(25). In the current study, we 160 
sequenced 215 patients with de novo DLBCL enrolled in the prospective, multicenter and 161 
randomized LYSA LNH-03B trials, using the Lymphopanel. Our intent was to determine 162 
whether the Lymphopanel was informative enough to identify targetable SNVs and/or 163 
pathway mutations that might alter treatment decisions, highlight subtype-specific mutational 164 
profiles, distinguish genes impacted by AID, and potentially foretell clinical outcome.  165 
 166 
 167 
Materials and Methods 168 
 169 
Patients 170 
215 adult patients with de novo CD20+ DLBCL enrolled in the prospective, multicenter and 171 
randomized LNH-03B LYSA trials with available frozen tumor samples, centralized 172 
histopathological review and adequate DNA/RNA quality were selected. The LNH03-B 173 
LYSA trials were initiated in 2003 and included 1704 patients overall in six distinct clinical 174 
trials (Supplementary Methods). COO molecular classification was obtained with 175 
HGU133+2.0 Affymetrix GeneChip arrays (Affymetrix), grouping patients into ABC, GCB, 176 
PMBL and “other”, also referred to as unclassified (detailed in Supplementary Methods). 177 
Clinical features of the patients are indicated in Table S1. The study was performed with 178 
approval of an institutional review board and written informed consent was obtained from all 179 
participants at the time of enrollment. 180 
 181 
NGS experiments and data analysis 182 
The Lymphopanel was designed to identify mutations in 34 genes important for 183 
lymphomagenesis, based on literature data (Table S2)(24) and WES of relapsed/refractory 184 
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DLBCL sequencing(25). The design covers 87 703 bases using 872 amplicons. Genes were 185 
grouped into 8 specific pathways: Immunity (CIITA, B2M, TNFRSF14 and CD58), NOTCH 186 
(NOTCH1 and NOTCH2), Apoptosis/Cell cycle (MFHAS1, XPO1, MYC, CDKN2A/B, 187 
FOXO1, TP53, GNA13 and BCL2), NFkB (TNFAIP3, MYD88, PIM1, CARD11, IRF4 and 188 
PRDM1), Epigenetic Regulation (EZH2, KMT2D, EP300, MEF2B and CREBBP), MAP 189 
Kinase (BRAF), JAK-STAT (SOCS1 and STAT6), and BCR (CD79A/B, ITPKB, TCF3 and 190 
ID3) (Table S3). 191 
Ion Torrent Personal Genome Machine (PGM) Sequencing and PGM data analysis was 192 
performed as previously described(26) and detailed in Supplementary Methods. Variant 193 
analysis was performed using an in-house generated bioinformatics pipeline, detailed in 194 
Supplementary Methods and Figures S1 and S2. This pipeline ensured excellent filtering of 195 
artefacts and polymorphisms, as proven by an independent study of seven non-tumoral 196 
samples from DLBCL patients with a mean error rate of non-filtered variants of only 0.7% 197 
(Table S4).  198 
 199 
Statistical methods 200 
All statistical analyses were performed using R software version 3.1.2(27). Progression-Free 201 
survival (PFS) was evaluated from the date of enrolment to the date of disease progression, 202 
relapse, re-treatment or death from any cause. Overall survival (OS) was evaluated from the 203 
date of enrolment to the date of death from any cause. Multivariate Cox and log-rank tests 204 
(“survival” R package version 2.37.7) were used to assess differences in OS and PFS rates 205 
calculated by Kaplan-Meir estimates. Ward hierarchical unsupervised clustering (“LPS” R 206 
package version 1.0.10) was performed using Jaccard distance. Statistical differences between 207 
all other parameters were determined using χ2, Mann-Whitney or Fisher’s exact tests when 208 
appropriate. P values or False Discovery Rates (FDR) < 0.05 were considered statistically 209 
significant. 210 
 211 
Results and Discussion 212 
 213 
Lymphopanel Variant Features 214 
Lymphopanel NGS was performed on 215 DLBCL patients (81 ABC, 83 GCB, 33 “other” 215 
and 18 PMBL). The median overall sequencing depth was 225x [110x-331x]. An initial 216 
13 965 variants were filtered for quality, SNPs and functional relevance, leading to 1064 217 
(7.6%) variants ultimately validated (Table S5 and Figure S1). The Lymphopanel 218 
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informativity was of 96%, with 206 patients (78 GCB, 80 ABC, 30 “other” and 18 PMBL) 219 
presenting at least one variant. All genes in the Lymphopanel were informative for at least 220 
one patient, with the number of variants per gene ranging from one to 124. Gene mutation 221 
frequencies in the total cohort and by subtype are presented in Figure 1.  222 
We subdivided the genes targeted by the Lymphopanel into eight specific pathways (Figure 2, 223 
Table S3). As expected, we confirmed that the ABC subtype is dominated by NFkB pathway 224 
mutations (45% of total variants), followed by epigenetic regulation pathway mutations 225 
(20.2% of total variants) (Figure 2A), whereas the GCB subtype is mostly characterized by 226 
mutations in the epigenetic regulation pathway (32.3% of total variants) and the apoptosis/cell 227 
cycle pathway (26.3% of total variants) (Figure 2B). Mutations in the JAK-STAT, immunity 228 
and apoptosis/cell cycle pathways were prevalent in PMBL (29.1%, 20.9% and 20.9% of total 229 
variants respectively) (Figure 2C). Interestingly, PMBL presented a significantly higher 230 
number of variants per sample than the other subtypes combined (p=2.76x10-5, Figure S3). 231 
The “other” subtype showed a fairly hybrid spectrum of pathway mutations (Figure 2D), 232 
perhaps suggesting the involvement of the three main subtypes, rather than the existence of a 233 
distinct entity. 234 
We sought to assess the impact of AID involvement in the Lymphopanel genes (detailed in 235 
Supplementary Methods and Figure S4). Genes with an AID mutation frequency superior to 236 
the average of that of the Lymphopanel are presented in Table S6. Previously identified SHM 237 
targets in DLBCL among these genes include MYC, PIM1, IRF4, BCL2, SOCS1 and 238 
CIITA(23). Potentially novel SHM targets include MFHAS1, PRDM1, GNA13, MYD88, 239 
ITPKB and NOTCH2. There was no significant difference in AID involvement between 240 
DLBCL subtypes. 241 
 242 
Lymphopanel NGS identifies mutations with potential treatment impact  243 
The Lymphopanel included genes whose mutations could serve to stratify patients according 244 
to treatment options. This includes actionable mutations, currently targeted by precision 245 
therapies, highlighted in Figure 1, as well as mutations whose presence might call into 246 
question the use of certain targeted therapy options. 247 
Recent results have shown that doubly mutated MYD88/CD79B patients are significantly 248 
more responsive to single therapy Ibrutinib, a BTK inhibitor, highlighting the importance of 249 
targeted NGS for DLBCL patients in the clinical setting(28). Furthermore, the presence of 250 
CARD11 and TNFAIP3 mutations has been shown to lead to decreased activity of both 251 
Ibrutinib and Sotrastaurin, a Protein Kinase C inhibitor(29,30). MYD88 mutations are frequent 252 
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in ABC DLBCL, L265P being the most prevalent variant (up to 29% in previous studies)(18). 253 
In our cohort, MYD88 mutations were significantly enriched in ABC patients (28.4%, 254 
FDR=4.7x10-3), with the L265P mutation present in 21% of ABC patients (Figures 3 and 255 
S5A). Of 17 ABC patients with MYD88 L265P mutations, we found ten (58.8%) with 256 
associated CD79B mutations, who might respond more favorably to Ibrutinib treatment. 257 
CD79B mutations were identified in 10.7% of total patients, slightly less than previously 258 
reported, but were significantly enriched in ABC DLBCL (24.7%, FDR=3.2x10-5), 259 
corroborating previous studies(13,31). Of note, two (11.8%) MYD88 L265P mutated ABC 260 
patients were CARD11 mutated and  two were TNFAIP3 mutated, potentially diminishing the 261 
effect of Ibrutinib and Sotrastaurin, while six (35.3%) were PRDM1 mutated (Figure S6).  262 
ABC cells have been shown to be addicted to IRF4 activity (32), responsible for 263 
Lenalidomide treatment response. 21 IRF4 variants were discovered in 7.9% of patients 264 
(13.6% of ABC, 4.8% of GCB, 0% of “other” and 11.1% of PMBL) (Figure 1). Although the 265 
impact on expression of these mutations was not analyzed, only one IRF4 variant was a stop-266 
gain mutation, indicating that expression is most likely at least conserved. Most of the non-267 
synonymous SNVs were clustered around amino acid positions 18 (two S18 variants and two 268 
G20 variants) and 99 (four C99R variants, SIFT scores=0) (Figure 4). Interestingly, IRF4 269 
mutations were almost equally frequent in PMBL and ABC in our cohort. Although IRF4 270 
addiction has not been demonstrated in PMBL, this predilection for IRF4 mutations, added to 271 
the well-known high expression of IRF4 in this subtype, may suggest a potential role for 272 
Lenalidomide treatment in this subtype as well, calling for further investigation of these 273 
mutations’ effects. 274 
Recently, small molecule inhibitors of PIM kinases have been developed and studied in 275 
DLBCL. In our cohort, PIM1 mutations were significantly skewed toward ABC (33.3%, 276 
FDR=3.3x10-5) in our cohort and represented 20.2% of ABC variants (Figures 2A, 3 and 277 
S5A). Of note, truncating PIM1 variants were predominant in ABC patients (13 of 14 278 
identified). Interestingly, DLBCL sensitivity to PIM kinase inhibitors is not correlated with 279 
the level of PIM kinase expression (33), suggesting that even expression-modifying PIM1 280 
mutations might not necessarily hamper the efficacy of PIM1 inhibitors, although this remains 281 
to be verified. In any case, the high frequency of PIM1 mutations in our cohort seems to 282 
justify the pre-screening of PIM kinase inhibitor candidate patients by PIM1 sequencing, in 283 
order to identify those most likely to benefit from this targeted therapy. 284 
The most highly mutated gene in GCB, BCL2(34), can notably be targeted by BH3-mimetics. 285 
Among our GCB cohort, BCL2 was the third most frequently mutated gene (24.1%, 286 
Research. 
on January 29, 2016. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on January 27, 2016; DOI: 10.1158/1078-0432.CCR-15-2305 
9 
 
FDR=2.5x10-5) (Figures 3 and S5B), with mutations most frequently impacting the amino 287 
terminus and between the BH1 and BH3 domains. The BH3 domain was not impacted, 288 
indicating that BH3 mimetic activity would not be hampered in these patients (Figure S7).  289 
Targeting epigenetic changes is also being increasingly explored in the realm of tailored 290 
therapy, notably among the GCB subtype, justifying the inclusion of genes such as EZH2, 291 
CREBBP, KMT2D and EP300 within the Lymphopanel. In our cohort, 18.1% of GCB patients 292 
were EZH2 mutated, mostly at the Y641 hotspot, and EZH2 mutations were enriched in GCB 293 
(FDR=1.8x10-3), as observed in previous studies, with no EZH2 mutated ABC patients(13) 294 
(Figures 3 and S5B). Interestingly, one PMBL patient presented an EZH2 Y641 mutation, 295 
adding to the debate of which DLBCL subtypes might benefit from EZH2 inhibitor 296 
treatment(26). CREBBP mutations were identified in 31.3% of GCB patients and 6.2% of 297 
ABC patients, corroborating previous studies(17), but were also found in 24.2% of “other” 298 
and 11.1% of PMBL (Figures 1 and S5). KMT2D mutations, evenly distributed throughout the 299 
coding sequence, were identified in 40.9% of our cohort, with KMT2D being the most 300 
frequently mutated gene in all subtypes except PMBL (Figure 1). Of the 124 variants, 78 were 301 
truncating mutations, indicating bias toward loss of protein expression. 302 
Mutations of master regulators TP53 and MYC showed no significant difference in subtype 303 
distribution in our cohort (Figure 3). TP53 variants were present in 14.9% of total patients 304 
(slightly less than previously reported(13,35)) (Figure 1) and several recurrent variants were 305 
identified, including six R248 variants, shown to be loss of function mutants in DLBCL(35). 306 
As for MYC, we discovered mutations in 6.5% of total patients (4.9% of ABC, 9.6% of GCB, 307 
3% of “other” and 5.6% of PMBL). No mutations were identified at the known hotspots in 308 
Burkitt Lymphoma (BL), including S62 and T58. 309 
Finally, although frequent mutations are most enticing for therapeutic potential, rare 310 
mutations can also be potentially very effectively actionable. For instance, BRAF and 311 
NOTCH1 mutations have been identified as rare but functionally relevant in DLBCL(13). In 312 
our cohort, we identified one patient with an activating V600E BRAF variant. As for 313 
NOTCH1, ten patients in our cohort presented mutations (Figure 1). TCF3 was mutated in 314 
three patients, all of whom harbored a pathogenic N551K variant, which has shown altered 315 
DNA-binding specificity(36). The negative regulator of TCF3, ID3, was mutated in 4.7% of 316 
patients (Figure 1), with most variants affecting the HLH domain (Figure S7), potentially 317 
impairing its ability to inactivate TCF3, as shown in BL(36). ID3 and TCF3 mutations have 318 
recently been shown to be of comparable frequency in BL and DLBCL, highlighting the 319 
overlap between these two entities(37). 320 
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 321 
The Lymphopanel highlights a unique PMBL mutational signature 322 
STAT6 and SOCS1 mutations were both very significantly enriched in PMBL (FDR=6.8x10-14 323 
and FDR=2.5x10-5 respectively), with STAT6 being the most frequently mutated gene in 324 
PMBL (72.2%, Figures 3 and S5C). All STAT6 mutations were non-synonymous SNVs and 325 
recurrent variants were frequent among PMBL, including seven N417 variants (Figure S7). 326 
SOCS1 mutations were present in 55.5% of PMBL patients, 30% of them harboring SOCS1 327 
inactivating mutations (Figure S5C). TNFAIP3 mutations have also been frequently identified 328 
in PMBL (up to 36%)(38). We found TNFAIP3 mutations to be significantly enriched in 329 
PMBL (61.1%, FDR=3.1x10-5), with all but one TNFAIP3 mutated PMBL patient harboring 330 
truncating mutations (Figures 3 and S5C). The frequent TNFAIP3 and SOCS1 mutations in 331 
PMBL highlight the similarities between PMBL and cHL(38,39). Furthermore, no MYD88, 332 
CD79B or CARD11 mutations were observed in PMBL patients (Figure 1), suggesting a 333 
PMBL dependence on TNFAIP3 mutations for the constitutive activation of NFkB. 334 
Interestingly, significant GNA13 mutation enrichment was shown in PMBL rather than GCB 335 
in our cohort (50%, FDR=2.8x10-4) (Figures 3 and S5), and one third of GNA13 variants were 336 
potentially truncating mutations (Figure 4). 337 
We discovered 46 B2M variants in 18.1% of total patients, significantly enriched in PMBL 338 
(50%, FDR=1.2x10-3) (Figures 1, 3 and S5C). Six of nine B2M mutated PMBL patients 339 
harbored truncating mutations and the remaining three presented pathogenic non-synonymous 340 
SNVs, two of which were a highly recurrent p.M1R variant predicted to affect the start codon 341 
(Figure 4). Recently, frequent B2M mutations leading to lack of protein expression were 342 
identified in cHL(9). Our similar findings in PMBL further highlight the molecular 343 
similarities between these two entities. CD58 variants were also significantly enriched in 344 
PMBL (FDR=1.2x10-3) (Figures 3 and S5), with five of seven CD58 mutated PMBL patients 345 
exhibiting truncating mutations, potentially leading to a lack of CD58 expression. 346 
Importantly, PD-1 blockade has recently shown promise as an effective treatment of relapsed 347 
or refractory cHL(40). Escape from T cell immunity via B2M and/or CD58 mutations could 348 
potentially affect the activity of PD-1 inhibitors in PMBL and cHL and warrants further 349 
investigation. Furthermore, we found 39 CIITA variants, enriched in PMBL as well (55.6% of 350 
PMBL versus 14.14% of total patients, FDR=3.1x10-5) (Figures 1, 3 and S5C). To our 351 
knowledge, this is the first study to identify truncating immunity pathway mutations as major 352 
in PMBL, although CIITA/PDL1-2 translocations had been shown to impact PMBL 353 
survival(41). 354 
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ITPKB, MFHAS1 and XPO1 mutations were identified as significantly overrepresented in a 355 
relapsed/refractory DLBCL patient cohort(25), leading to their inclusion in the Lymphopanel. 356 
In our cohort, ITPKB, MFHAS1 and XPO1 mutations were all identified for the first time as 357 
being significantly enriched in PMBL patients (FDR=1.4x10-2, FDR=3.9x10-3 and 358 
FDR=4.8x10-10 respectively, Figure 3). The roles of ITPKB and MFHAS1 in 359 
lymphomagenesis are not yet fully elucidated. ITPKB regulates B cell survival and function, 360 
and ITPKB deficiency leads to B cell antigen presentation unresponsiveness and decreased B 361 
cell survival, associated with specific overexpression of proapoptotic Bim protein(42). We 362 
found 48 ITPKB variants, present in 14% of total patients (Figures 1 and S5). ITPKB 363 
mutations were uniformly distributed along the protein sequence, excepting the seemingly 364 
conserved catalytic IPK domain, affected by only two non-synonymous SNVs (Figure 4). 365 
MFHAS1 is a potential oncogene with highly conserved leucine-rich tandem repeats, isolated 366 
from a minimal common amplified region in malignant fibrous histiocytomas at 8p23.1. 367 
MFHAS1 is also a target gene for chromosomal translocation t(8;14)(p23.1;q21) in B-cell 368 
lymphoma cell lines and has been shown to be tumorigenic in nude mice(43). In our cohort, 369 
MFHAS1 variants were identified in 7.9% of total patients, and were distributed 370 
homogeneously along the coding sequence, with no recurrent mutations identified (Figure 4). 371 
Although the role of these potential oncogenes in lymphomagenesis is still unclear, their high 372 
mutation frequency in PMBL especially warrants further investigation. 373 
As for XPO1, it encodes CRM1, an exporter of several tumor suppressor proteins (TSPs). 374 
Cytoplasmic export of TSPs renders them inactive, indicating that XPO1 acts as a proto-375 
oncogene. XPO1 mutations were present in 4.7% of total patients (1.2% of ABC, 1.2% of 376 
GCB, 3% of “other” and 38.9% of PMBL) (Figures 1 and S5). The mutation identified is 377 
recurrent, with all variants affecting E571 (Figure 4), as previously found in rare CLL cases 378 
(<5%)(44). Importantly, Selective Inhibitors of Nuclear Export (SINEs), have been shown to 379 
effectively target CRM1 and retain TSPs in the nucleus(45). Given the frequency of XPO1 380 
E571 mutations in PMBL, further investigation concerning their impact on response to SINEs 381 
is warranted (Jardin et al, under review). 382 
 383 
Identification of gene mutations correlated with clinical characteristics and prognosis 384 
We tested each gene in the Lymphopanel for correlation with clinical characteristics including 385 
age, stage, IPI, bone marrow involvement and presence of bulky disease. 386 
CD79B, KMT2D and MYD88 mutations were significantly correlated with age (Figure S8). 387 
For CD79B and MYD88 mutations, enriched in ABC, this might be linked to the significantly 388 
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higher age of ABC patients (p=1.01x10-7 in our cohort)(46). As for KMT2D mutations, 389 
homogenous among subtypes, this result potentially suggests an accumulation of passenger-390 
type mutations, particularly visible in this long gene (16.6 kb sequenced). MYD88 mutations 391 
were also significantly correlated with higher IPI (FDR=0.04). 392 
On the other hand, PMBL patients were significantly younger (p=1.21x10-8) and the large 393 
majority of genes whose mutations were significantly enriched in PMBL were also correlated 394 
with younger age (Figure S8). In addition, B2M and immunity pathway mutations were 395 
significantly inversely correlated with Ann Arbor stage (FDR=3.2x10-3 and FDR=0.045 396 
respectively), and B2M and STAT6 mutations were significantly inversely correlated with IPI 397 
(FDR=5.5x10-4 and FDR=0.026 respectively). 398 
As expected, OS and PFS decreased with increasing IPI and ABC patients displayed 399 
significantly worse OS and PFS than GCB patients in the R-CHOP treatment group 400 
(p=1.9x10-2 and p=6.6x10-3 respectively) (Figure S9). Of note, PMBL patients in our cohort 401 
did not present the favorable prognosis typically associated with this subtype(47), perhaps due 402 
to the lack of dedicated treatment. 403 
Prognostic impact was assessed for all Lymphopanel genes and subtypes, among patients 404 
treated with R-chemotherapy, separated into an R-CHOP group and an R-ACVBP group. 405 
Analyses over all subtypes were performed using multivariate Cox tests, while analyses of 406 
each subtype individually were performed using log-rank tests. In both cases, independent 407 
corrections of p-values were performed for OS and PFS. Gene mutations harboring prognostic 408 
impacts with uncorrected p-values < 0.05 are highlighted in Table 1 and Figure S10, and all 409 
survival analyses are presented in Table S7. We set an FDR threshold of 0.05 to detect gene 410 
mutations with significant prognostic impacts. 411 
Among ABC DLBCL treated with R-CHOP, TNFAIP3 mutations were significantly 412 
associated with lower OS (FDR=7.86x10-4) and PFS (FDR=3.04x10-2), while GNA13 413 
mutations were significantly associated with lower PFS (FDR=3.04 x10-2), (Figure 5). Of 414 
note, the poor prognostic impact of these mutations was not observed in patients treated with 415 
R-ACVBP, which, for TNFAIP3 at least, might be linked to the improved survival observed 416 
in younger patients with DLBCL treated with R-ACVBP(48). These findings need to be 417 
confirmed in an independent cohort of patients, given the small sample size. 418 
Unfortunately, the prognostic impact of TNFAIP3 mutations in PMBL patients could not be 419 
assessed due to the existence of only one WT TNFAIP3 PMBL patient treated with R-CHOP 420 
(Table S7). Moreover, previously described prognostic impacts of TP53, FOXO1 or MYD88 421 
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mutations were not confirmed(35,49,50), although the impact of specific deleterious 422 
mutations was not analyzed on its own. 423 
 424 
In conclusion, NGS is increasingly accessible in academic research settings, but its 425 
possibilities in routine clinical settings have yet to be thoroughly harnessed. This study has 426 
shown that, by using a restricted set of genes, not only can well-known mutations be tracked, 427 
but novel or rare mutations can also be identified and potentially targeted as well. Detailing 428 
subtype-enriched gene and pathway mutations is critical for optimal understanding and 429 
treatment of DLBCL: here, we have added to the field’s current knowledge of the genetic 430 
heterogeneity between DLBCL subtypes, and identified novel clinical and prognostic 431 
correlations, which might also have an impact on therapeutic decisions. NGS with a 432 
consensus targeted panel could contribute valuable information to multidisciplinary meetings 433 
and constitute a molecular breakthrough in the way treatment decisions are made, by 434 
providing personalized mutational profiles of actionable targets. Furthermore, although this 435 
study was performed on frozen tumor samples, which are of limited availability, the 436 
Lymphopanel was designed to be effective in FFPE samples as well, further cementing its 437 
capacity to play an essential role in clinical disease management. In addition, our team has 438 
recently demonstrated that Lymphopanel NGS can be successfully performed using plasma-439 
extracted cell-free circulating DNA, highlighting its feasibility and potential role in the 440 
monitoring of DLBCL(51). Taken together, these results serve as proof-of-principle that NGS 441 
with a consensus gene panel can alter the manner in which DLBCL patients are subclassified 442 
and treated. 443 
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 457 
Figure and Table Legends 458 
Figure 1: Mutation frequencies in the total cohort and by subtype. Mutation frequencies 459 
in the total cohort are represented as a stacked bar chart. The number at the top of each bar 460 
represents the mutation frequency of the indicated gene in the total cohort. Bars are 461 
subdivided by DLBCL subtype, with segments proportional to mutation frequency. 462 
Potentially actionable targets are highlighted by indicating the appropriate class of molecule, 463 
which could potentially be used. 464 
Figure 2: Mutation pathway heterogeneity among DLBCL subtypes. Pie-chart 465 
representations of mutation frequencies represented by pathway are represented for ABC (A), 466 
GCB (B), PMBL (C) and Other (D) subtypes. Mutation frequencies per gene and per subtype 467 
are shown here as the percentage of the total number of variants. Genes were grouped into 8 468 
specific pathways: Immunity (CIITA, B2M, TNFRSF14 and CD58), NOTCH (NOTCH1 and 469 
NOTCH2), Apoptosis/Cell Cycle (MFHAS1, XPO1, MYC, CDKN2A/B, FOXO1, TP53, 470 
GNA13 and BCL2), NFkB (TNFAIP3, MYD88, PIM1, CARD11, IRF4 and PRDM1), 471 
Epigenetic Regulation (EZH2, KMT2D, EP300, MEF2B and CREBBP), MAP Kinases 472 
(BRAF), JAK-STAT (SOCS1 and STAT6), and BCR (CD79A/B, ITPKB, TCF3 and ID3).  473 
Figure 3: Heatmap of mutation frequencies by subtype. Mutation frequencies in each 474 
subtype are indicated for each gene of the Lymphopanel. Mutation frequencies per gene and 475 
per subtype are shown here as the percentage of the total number of patients. Statistical 476 
significance of gene mutation enrichment in a given subtype is indicated by the FDR column. 477 
The horizontal line separates genes with FDR<0.05, considered significant, from genes with 478 
FDR≥0.05.  479 
Figure 4. Mutations at the protein level. Protein representations were rendered using 480 
domains imported from the Pfam database (green). Exons were located using the CCDS 481 
database and were numbered automatically, not counting non-coding and spliced exons. 482 
Substitutions are depicted as diamonds, insertions as triangles and deletions as rectangles 483 
whose length varies according to the deletion size. A color code is also applied, with blue 484 
indicating non-synonymous substitutions or non-frameshift insertions, yellow indicating 485 
insertions and frameshift deletions, and pink indicating stop-gain and stop-loss mutations. 486 
Blue shading indicates sequenced regions. 487 
Figure 5: TNFAIP3 and GNA13 mutations are linked to worse prognosis in R-CHOP-488 
treated ABC patients. Survival analysis was performed on ABC patients treated with R-489 
CHOP according to the presence or absence of TNFAIP3 mutation (A, B) or GNA13 mutation 490 
(C, D). Both TNFAIP3 and GNA13 mutations are associated with significantly less favorable 491 
prognosis in R-CHOP treated ABC patients. 492 
Table 1. Prognostic impact of gene mutations among the Lymphopanel. Gene mutations 493 
with a tendency toward prognostic impact (uncorrected p<0.05) are indicated, for OS and/or 494 
PFS. The subtype and treatment cohort in which a prognostic impact was identified is shown, 495 
as is the number of mutant and WT patients for each survival analysis. HR column indicates 496 
Hazard Ratio. Bold type highlights significant FDR values. 497 
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Gene Subtype Cohort Type Mutant (n) WT (n) HR p FDR 
TNFAIP3 ABC R-CHOP OS 6 48 9.04 [2.82-28.98] 9.03E-06 7.86E-04 
TNFAIP3 ABC R-CHOP PFS 6 48 5.59 [1.91-16.39] 4.29E-04 3.04E-02
GNA13 ABC R-CHOP PFS 5 49 5.89 [1.86-18.64] 6.47E-04 3.04E-02 
B2M all R-CHOP PFS 16 100 0.12 [0.03-0.55] 6.24E-03 3.25E-01 
B2M all R-CHOP OS 16 100 0.11 [0.01-0.82] 3.13E-02 5.43E-01 
IRF4 all R-CHOP OS 10 106 2.53 [1.10-5.87] 2.98E-02 5.43E-01 
CD79B all R-CHOP OS 19 97 0.31 [0.11-0.90] 3.13E-02 5.43E-01
CD79B all R-CHOP PFS 19 97 0.29 [0.10-0.83] 2.15E-02 5.58E-01 
CD58 all R-CHOP PFS 12 104 2.36 [1.07-5.20] 3.27E-02 5.67E-01 
GNA13 ABC R-CHOP OS 5 49 3.68 [1.21-11.15] 1.36E-02 5.94E-01 
FOXO1 GC R-CHOP OS 5 35 3.87 [1.00-15.07] 3.53E-02 7.72E-01 
CD79B ABC R-CHOP OS 16 38 0.35 [0.12-1.02] 4.44E-02 7.72E-01
CD79B ABC R-CHOP PFS 16 38 0.33 [0.11-0.95] 3.07E-02 8.30E-01 
 
Table 1. Prognostic impacts of gene mutations among the Lymphopanel 
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